Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17335692 | 0.80 | POLB (0.44) | HPGDROCK2 | |
| SCHEMBL14709912 | 0.79 | ALDH1A1 (0.33) | HPGDROCK1 | |
| SCHEMBL17335671 | 0.78 | AOC3 (0.45) | P2RX7 | |
| SCHEMBL5830160 | 0.75 | ROCK1 (0.32) | PTGESROCK1 | |
| SCHEMBL1456919 | 0.74 | P2RX7 (0.49) | P2RX7HPGD | |
| SCHEMBL1456923 | 0.74 | P2RX7 (0.49) | P2RX7HPGD | |
| SCHEMBL31036978 | 0.74 | P2RX7 (0.49) | P2RX7HPGD | |
| SCHEMBL12880436 | 0.72 | MEN1 (0.36) | — | |
| SCHEMBL23417762 | 0.72 | TRPV1 (0.51) | — | |
| SCHEMBL25558429 | 0.72 | MMP13 (0.46) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | P2RX7 2085/4885HPGD 137/4885PTGES 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.